Annual SG&A
$20.80 M
-$28.00 K-0.13%
31 December 2023
Summary:
Inozyme Pharma annual selling, general & administrative expenses is currently $20.80 million, with the most recent change of -$28.00 thousand (-0.13%) on 31 December 2023. During the last 3 years, it has risen by +$10.25 million (+97.17%). INZY annual SG&A is now -0.13% below its all-time high of $20.83 million, reached on 31 December 2022.INZY Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$4.96 M
-$946.00 K-16.01%
30 September 2024
Summary:
Inozyme Pharma quarterly selling, general & administrative expenses is currently $4.96 million, with the most recent change of -$946.00 thousand (-16.01%) on 30 September 2024. Over the past year, it has increased by +$228.00 thousand (+4.82%). INZY quarterly SG&A is now -23.82% below its all-time high of $6.51 million, reached on 31 March 2023.INZY Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.29 B
-$96.49 M-8.07%
30 September 2024
Summary:
Inozyme Pharma TTM selling, general & administrative expenses is currently -$1.29 billion, with the most recent change of -$96.49 million (-8.07%) on 30 September 2024. Over the past year, it has dropped by -$1.31 billion (-6064.27%). INZY TTM SG&A is now -3629.65% below its all-time high of $22.31 million, reached on 31 March 2023.INZY TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INZY Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -0.1% | +4.8% | -6064.3% |
| 3 y3 years | +97.2% | +0.9% | -7298.0% |
| 5 y5 years | +495.3% | +394.6% | -10000.0% |
INZY Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -0.1% | +97.2% | -23.8% | +5.1% | -195.9% | at low |
| 5 y | 5 years | -0.1% | +495.3% | -23.8% | +394.6% | -3629.7% | at low |
| alltime | all time | -0.1% | +495.3% | -23.8% | +394.6% | -3629.7% | at low |
Inozyme Pharma Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $4.96 M(-16.0%) | $20.93 M(+1.1%) |
| June 2024 | - | $5.91 M(+12.9%) | $20.70 M(+6.0%) |
| Mar 2024 | - | $5.23 M(+8.5%) | $19.52 M(-6.1%) |
| Dec 2023 | $20.80 M(-0.1%) | $4.83 M(+1.9%) | $20.80 M(-4.0%) |
| Sept 2023 | - | $4.73 M(+0.1%) | $21.67 M(+0.1%) |
| June 2023 | - | $4.73 M(-27.4%) | $21.66 M(-2.9%) |
| Mar 2023 | - | $6.51 M(+14.3%) | $22.31 M(+7.1%) |
| Dec 2022 | $20.83 M(+10.0%) | $5.70 M(+20.7%) | $20.83 M(+2.4%) |
| Sept 2022 | - | $4.72 M(-12.3%) | $20.34 M(-0.9%) |
| June 2022 | - | $5.38 M(+7.1%) | $20.53 M(+4.8%) |
| Mar 2022 | - | $5.03 M(-3.5%) | $19.58 M(+3.5%) |
| Dec 2021 | $18.93 M | $5.21 M(+5.9%) | $18.93 M(+5.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $4.92 M(+10.8%) | $17.95 M(+11.0%) |
| June 2021 | - | $4.43 M(+1.5%) | $16.18 M(+20.6%) |
| Mar 2021 | - | $4.37 M(+3.2%) | $13.42 M(+27.2%) |
| Dec 2020 | $10.55 M(+130.0%) | $4.24 M(+34.8%) | $10.55 M(+35.2%) |
| Sept 2020 | - | $3.14 M(+88.0%) | $7.80 M(+37.8%) |
| June 2020 | - | $1.67 M(+11.4%) | $5.66 M(+12.0%) |
| Mar 2020 | - | $1.50 M(+0.7%) | $5.06 M(+10.2%) |
| Dec 2019 | $4.59 M(+31.3%) | $1.49 M(+48.5%) | $4.59 M(+48.1%) |
| Sept 2019 | - | $1.00 M(-5.7%) | $3.10 M(+47.9%) |
| June 2019 | - | $1.06 M(+3.3%) | $2.09 M(+103.3%) |
| Mar 2019 | - | $1.03 M | $1.03 M |
| Dec 2018 | $3.49 M | - | - |
FAQ
- What is Inozyme Pharma annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Inozyme Pharma?
- What is Inozyme Pharma annual SG&A year-on-year change?
- What is Inozyme Pharma quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Inozyme Pharma?
- What is Inozyme Pharma quarterly SG&A year-on-year change?
- What is Inozyme Pharma TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Inozyme Pharma?
- What is Inozyme Pharma TTM SG&A year-on-year change?
What is Inozyme Pharma annual selling, general & administrative expenses?
The current annual SG&A of INZY is $20.80 M
What is the all time high annual SG&A for Inozyme Pharma?
Inozyme Pharma all-time high annual selling, general & administrative expenses is $20.83 M
What is Inozyme Pharma annual SG&A year-on-year change?
Over the past year, INZY annual selling, general & administrative expenses has changed by -$28.00 K (-0.13%)
What is Inozyme Pharma quarterly selling, general & administrative expenses?
The current quarterly SG&A of INZY is $4.96 M
What is the all time high quarterly SG&A for Inozyme Pharma?
Inozyme Pharma all-time high quarterly selling, general & administrative expenses is $6.51 M
What is Inozyme Pharma quarterly SG&A year-on-year change?
Over the past year, INZY quarterly selling, general & administrative expenses has changed by +$228.00 K (+4.82%)
What is Inozyme Pharma TTM selling, general & administrative expenses?
The current TTM SG&A of INZY is -$1.29 B
What is the all time high TTM SG&A for Inozyme Pharma?
Inozyme Pharma all-time high TTM selling, general & administrative expenses is $22.31 M
What is Inozyme Pharma TTM SG&A year-on-year change?
Over the past year, INZY TTM selling, general & administrative expenses has changed by -$1.31 B (-6064.27%)